pharmaceuticals-and-healthcare

United States Acinetobacter Infections Treatment Market Report 2018


Published On : Jan 2018

Category : Healthcare IT

No. of Pages : 128 pages

  • $3800
  • $7600

SPECIFY YOUR RESEARCH NEED

  • Query Type :
  •  

In the last several years, global market of Acinetobacter Infections Treatment developed rapidly, with an average growth rate of 2.96%. In 2016, United States Market Size of Acinetobacter Infections Treatment is nearly 22 M USD. For developing product, there are 1 in Phase III, 1 in Phase ?, 4 in Phase 1 and 8 in Preclinical. The total investment for Acinetobacter Infections Treatmen Drugs developing is around 90 M USD.

This report studies the Acinetobacter Infections Treatment development status and future trend in United States, focuses on top players in United States, also splits Acinetobacter Infections Treatment by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in United States market include 
Entasis Therapeutics
Roche 
Adenium Biotech
Vaxdyn 
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals

Geographically, this report splits the United States market into six regions, 
Northeast
South Atlantic
West South Central
East North Central
Pacific
Other


On the basis of product, the Acinetobacter Infections Treatment market is primarily split into 
Sulbactam
Carbapenems 
Aminoglycosides
Polymyxins
Tetracyclines
Others

On the basis on the Pipeline this report covers 
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small molecule antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
eCAPs
SLP0904
S-649266 (cefiderocol)
Gram Negative (AcB)
TP-6076

Healthcare IT or information technology refers to information technology that is applied to health and health care related activities. It backs health information management across several computerized systems and helps in safe exchange of health related data between quality monitors, payers, providers, and consumers. Healthcare IT helps improving the quality and effectiveness of healthcare, increase productivity, decrease costs of healthcare, and enhance administrative efficiency among others. The healthcare IT industry is expected to progress significantly over the coming years owing to the rising needs to administer regulatory compliances through solutions of healthcare IT.

The research study offers an exclusive rundown of the factors that are expected to have a lasting or short term impact on the growth of the United states acinetobacter infections treatment market report 2018 market during the forecast period. The report perfectly explores elements that are expected to have a stimulus or delayed effect on the United states acinetobacter infections treatment market report 2018 market in the short or long run. The growth trajectory of the market has also been minutely studied with special attention on the drivers, restraints, and prospects present in the United states acinetobacter infections treatment market report 2018 market for the players and investors to look on to. Several facets such as inflow of raw materials and outflow of end products, imports and exports, strategies and protocols of governments, performance of the market in the global and regional level, products distributed and sold, and industrialized capacity of the industrial unit have also been emphasized upon in the study.

Varied regions where the market is set-up have also been paid attention to and the elements at play assisting or hindering the expansion of the market in those regions. The report also provides an inclusive outlook of the elite companies operating in the United states acinetobacter infections treatment market report 2018 market. With the help of this, the reader can have a clear picture of the competitive landscape of the players and a comprehension of the products and marketing tactics of the leading players in the United states acinetobacter infections treatment market report 2018 market. 

List of Tables and Figures

Figure Product Picture of Acinetobacter Infections Treatment 1
Table United States Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate Comparison by Types (Product Category) (2012-2023) 2
Figure United States Acinetobacter Infections Treatment Revenue Market Share by Types (Product Category) in 2016 3
Figure Sulbactam Product Picture 4
Figure Carbapenems Product Picture 4
Figure Aminoglycosides Product Picture 5
Figure Polymyxins Product Picture 6
Figure Tetracyclines Product Picture 7
Table United States Acinetobacter Infections Treatment Comparison by Pipeline in 2017 7
Figure United States Acinetobacter Infections Treatment Comparison by Pipeline in 2017 8
Figure United States Acinetobacter Infections Treatment Market Size (M USD) Comparison by Regions (2012-2023) 9
Figure Northeast Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 10
Figure South Atlantic Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 11
Figure West South Central Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 12
Figure East North Central Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 13
Figure Pacific of US Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 14
Figure United States Acinetobacter Infections Case and Growth Rate (2012-2023) 15
Figure United States Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 16
Table United States Acinetobacter Infections Treatment Pipeline of Key Players/Manufacturers 2017 17
Table United States Acinetobacter Infections Treatment R&D Investment (M USD) by Players/Manufacturers (2016-2017) 18
Table United States Acinetobacter Infections Treatment R&D Investment Market Share by Players/Manufacturers (2016-2017) 18
Figure 2016 United States Acinetobacter Infections Treatment R&D Investment Market Share by Players/Manufacturers 19
Figure 2017 United States Acinetobacter Infections Treatment R&D Investment Market Share by Players/Manufacturers 20
Figure 2017 United States Acinetobacter Infections Treatment R&D Investment Market Share by Players/Manufacturers 21
Figure United States Acinetobacter Infections Treatment R&D Investment Market Share of Top 3 Players/Manufacturers 22
Figure United States Acinetobacter Infections Treatment R&D Investment Market Share of Top 5 Players/Manufacturers 23
Table United States Players/Manufacturers Acinetobacter Infections Treatment Headquarters and Established 23
Table United States Players/Manufacturers Acinetobacter Infections Treatment Product Pipeline 24
Table United States Acinetobacter Infections Case by Regions (2012-2017) 25
Table United States Acinetobacter Infections Case Share by Regions (2012-2017) 25
Figure United States Acinetobacter Infections Treatment Sales Share by Regions (2012-2017) 26
Figure United States Acinetobacter Infections Treatment Sales Market Share by Regions in 2016 26
Table United States Acinetobacter Infections Treatment Revenue (M USD) and Market Share by Regions (2012-2017) 27
Table United States Acinetobacter Infections Treatment Revenue Market Share by Regions (2012-2017) 27
Figure United States Acinetobacter Infections Treatment Revenue Market Share by Regions (2012-2017) 28
Figure United States Acinetobacter Infections Treatment Revenue Market Share by Regions in 2016 28
Table United States Acinetobacter Infections Treatment Cost (USD/Case) by Regions (2012-2017) 29
Table Dosing information, Acquisition and Administration Costs 29
Table United States Acinetobacter Infections Treatment Revenue (M USD) and Market Share by Type (2012-2017) 30
Table United States Acinetobacter Infections Treatment Revenue Market Share by Type (2012-2017) 30
Figure Revenue Market Share of Acinetobacter Infections Treatment by Type (2012-2017) 31
Figure Revenue Market Share of Acinetobacter Infections Treatment by Type in 2016 32
Figure United States Acinetobacter Infections Treatment Sales Growth Rate (%) by Type (2012-2017) 33
Table United States Acinetobacter Infections Treatment Pipeline of Key Players/Manufacturers 2017 34
Table S-649266 (cefiderocol) Introduction 40
Table Entasis Therapeutics Company Profile 41
Table Acinetobacter Infections Treatment Product Introduction of Entasis Therapeutics 42
Table Product, Stage and Investment (M USD) of Entasis Therapeutics 2016-2016 43
Table Roche Company Profile 43
Table Acinetobacter Infections Treatment Product Introduction of Roche 44
Table Product, Stage and Investment (M USD) of Roche 2016-2016 45
Table Adenium Biotech Company Profile 45
Table Acinetobacter Infections Treatment Product Introduction of Adenium Biotech 46
Table Product, Stage and Investment (M USD) of Adenium Biotech 2016-2016 47
Table Vaxdyn Company Profile 47
Table Acinetobacter Infections Treatment Product Introduction of Vaxdyn 48
Table Product, Stage and Investment (M USD) of Vaxdyn 2016-2016 49
Table Hsiri Therapeutics Company Profile 49
Table Acinetobacter Infections Treatment Product Introduction of Hsiri Therapeutics 50
Table Product, Stage and Investment (M USD) of Hsiri Therapeutics 2016-2016 51
Table Aridis Pharmaceuticals Company Profile 51
Table Acinetobacter Infections Treatment Product Introduction of Aridis Pharmaceuticals 52
Table Product, Stage and Investment (M USD) of Aridis Pharmaceuticals 2016-2016 53
Table LegoChem Biosciences Company Profile 53
Table Acinetobacter Infections Treatment Product Introduction of LegoChem Biosciences 54
Table Product, Stage and Investment (M USD) of LegoChem Biosciences 2016-2016 55
Table Atterx Biotherapeutics Company Profile 55
Table Acinetobacter Infections Treatment Product Introduction of Atterx Biotherapeutics 56
Table Product, Stage and Investment (M USD) of Atterx Biotherapeutics 2016-2016 57
Table Achaogen Company Profile 57
Figure Acinetobacter Infections Treatment Product Introduction of Achaogen 58
Table Product, Stage and Investment (M USD) of Achaogen 2016-2016 59
Table Peptilogics Company Profile 59
Table Acinetobacter Infections Treatment Product Introduction of Peptilogics 60
Table Product, Stage and Investment (M USD) of Peptilogics 2016-2016 60
Table Sealife PHARMA Company Profile 61
Table Acinetobacter Infections Treatment Product Introduction of Sealife PHARMA 62
Table Product, Stage and Investment (M USD) of Sealife PHARMA 2016-2016 62
Table Shionogi Company Profile 63
Table Acinetobacter Infections Treatment Product Introduction of Shionogi 64
Table Product, Stage and Investment (M USD) of Shionogi 2016-2016 64
Table Techulon Company Profile 64
Figure Acinetobacter Infections Treatment Product Introduction of Techulon 65
Table Product, Stage and Investment (M USD) of Techulon 2016-2016 66
Table Tetraphase Pharmaceuticals Company Profile 66
Table Acinetobacter Infections Treatment Product Introduction of Tetraphase Pharmaceuticals 67
Table Product, Stage and Investment (M USD) of Tetraphase Pharmaceuticals 2016-2016 67
Figure typical phases from research to the market for a drug candidate 69
Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound 70
Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound 71
Figure Manufacturing Cost Structure of Acinetobacter Infections Treatment 71
Figure Assessment of API Manufacturing Cost By Region 72
Figure USA Overview of Average Hourly Wages 2015-2016 (USD/Hour) 73
Figure USA Overview of Labor Costs 2013-2016 (110 Index Points) 73
Figure Cost of Employing a Factory Worker 75
Figure 2015 Estimated Labor Costs for the Whole Economy in Europe 76
Figure Monthly Minimum Wages in Asia 2016 77
Figure China Overview of Average Yearly Wages 2015-2016 (CNY/Year) 78
Figure Japan Overview of Average Monthly Wages 2015-2016(JPY Thousand/Month) 78
Table 2015 Global Electricity Price of Industry (USD/KWh) by Country 79
Figure Manufacturing Process Analysis of Acinetobacter Infections Treatment 80
Figure Acinetobacter Infections Treatment Industrial Chain Analysis 81
Table Major Buyers of Acinetobacter Infections Treatment 82
Figure Marketing Channel for Biopharmaceuticals 85
Table Some of Famous Hospital 91
Table Distributors/Traders List 93
Table Multidrug-resistant Acinetobacter in USA 94
Figure Multidrug-resistant Acinetobacter in USA 95
Figure Global GDP Growth Rate for 2016 96
Figure US GDP 2006-2016 (Billion USD) 97
Figure US CPI Change 2016-2017 97
Figure EU GDP 2006-2016 (Billion USD) 98
Figure EU CPI Change 2012-2016 98
Figure Germany GDP 2006-2016 (Billion USD) 99
Figure Germany CPI Change 2016-2017 99
Figure UK GDP 2006-2016 (Billion USD) 99
Figure UK CPI Change 2016-2017 100
Figure Italy GDP 2006-2016 (Billion USD) 100
Figure Italy CPI Change 2016-2017 101
Figure Japan GDP 2006-2016 (Billion USD) 101
Figure Japan CPI Change 2012-2016 102
Figure China GDP 2006-2016 (Billion USD) 102
Figure China CPI Change 2016-2017 103
Figure United States Acinetobacter Infections Case and Growth Rate Forecast (2018-2023) 104
Figure United States Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate Forecast (2018-2023) 105
Table United States Acinetobacter Infections Treatment Market Size (M USD) Forecast by Type (2018-2023) 105
Figure United States Acinetobacter Infections Treatment Market Size Share Forecast by Type (2018-2023) 106
Figure United States Acinetobacter Infections Treatment Market Size Share Market Share Forecast by Type in 2023 106
Table United States Acinetobacter Infections Treatment Market Size (M USD) Forecast by Regions (2018-2023) 107
Table United States Acinetobacter Infections Treatment Market Size Share Forecast by Regions (2018-2023) 107
Figure United States Acinetobacter Infections Treatment Market Size Share Forecast by Regions (2018-2023) 108
Figure United States Acinetobacter Infections Treatment Market Size Share Forecast by Regions in 2023 108
Table Research Programs/Design for This Report 110
Figure Bottom-up and Top-down Approaches for This Report 112
Figure Data Triangulation 113
Table Key Data Information from Secondary Sources 114
Table Key Data Information from Primary Sources 115

Send an Enquiry

  • * :
  • * :
  • :
  • :
  • * :
  • :
  • * :
  • * indicates required field.

LATEST NEWS


Back To Top